/UPDATE -- Nektar Therapeutics/
Key Highlights
- ➤SALT Score ≤20 maintained in 75% after four months off treatment
- ➤SALT Score ≤20 maintained in 63% after six months off treatment
- ➤SALT Score ≤10 responses increased from 7% to 19% after six months off treatment
- ➤Third Phase 3 ZENITH AD study initiated in treatment-experienced patients
- ➤Phase 3 ZENITH AA study to initiate in early 2027
Expert Statements
David Rosmarin, M.D., Chair of the Department of Dermatology and Associate Professor of Dermatology at Indiana University School of Medicine
“These data demonstrate that one year of treatment with rezpegaldesleukin can result in lasting and even deepening hair regrowth with these same effects continuing for six months off-treatment in the majority of patients. As a novel Treg-targeted mechanism, rezpegaldesleukin is designed to address the underlying immune dysregulation in patients with alopecia areata. To date, we have not seen this degree of both sustained benefit and further hair regrowth after treatment cessation with existing systemic therapies for alopecia areata. These findings suggest that rezpegaldesleukin may offer a fundamentally different approach to managing this chronic disorder and could emerge as a preferred first-line treatment option in the future for patients seeking durable disease control.”
Thomas Bieber, M.D., Ph.D., Professor, Department of Dermatology and Allergy, Ludwig-Maximilians University Hospital, Munich, Germany
“Rezpegaldesleukin demonstrated a high maintenance of response and further deepening of response that speaks to the unique therapeutic approach of a regulatory Tcell agonist in patients with atopic dermatitis. With both monthly and quarterly maintenance dosing, new and sustained responses were observed across the key endpoints of EASI-75, vIGA-AD 0/1 and Itch NRS, with some patients achieving complete skin clearance, or EASI-100. These novel data support the ongoing Phase 3 studies and also highlight the importance of a Treg mechanism to address the heterogeneity of disease in atopic dermatitis patients.”
Jonathan Zalevsky, Ph.D., Chief Research and Development Officer at Nektar Therapeutics
“These results continue to grow the body of evidence that Treg stimulation is emerging as a durable and well-tolerated potential therapeutic option in two distinct immune dermatologic patient populations and support rezpegaldesleukin's advancement into pivotal trials in both atopic dermatitis and alopecia areata. We've now initiated the third Phase 3 study for rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis who have had prior systemic biologic and/or JAK inhibitor treatment experience and we are initiating the Phase 3 ZENITH AA study in alopecia areata in early 2027.”
In the news release, New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026, issued 01-Oct-2026 by Nektar Therapeutics over PR Newswire, formatting irregularities were introduced by PR Newswire in error throughout the release upon distribution. The complete, corrected release follows: New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 Rezpegaldesleukin demonstrated durability and deepening of response through one year of treatment in two dermatological indications, reinforcing the differentiated properties of this novel Treg mechanism
In alopecia areata patients, SALT Score ≤20 response maintained in 75% at 4 months off treatment and in 63% at six months off treatment
Get started
Create a free account to read the full story.